 | |
| Company type | Private |
|---|---|
| LSE: DPH | |
| Industry | Pharmaceuticals |
| Founded | 1997 |
| Headquarters | Northwich, England, UK |
Key people | Jesper Nordengaard, (CEO) |
| Revenue |  £681.8 million (2022)[1] |
| £174.3 million (2022)[1] | |
| £58.2 million (2022)[1] | |
Number of employees | 2,036 (2022)[1] |
| Website | www |
Dechra is a business involved in the development and marketing ofveterinary products based inNorthwich, England. It was listed on theLondon Stock Exchange until it was acquired byEQT AB in January 2024.
The Company was founded in 1997 by way of amanagement buy-out fromLloyds Chemists.[2] It was first listed on theLondon Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62 million.[3] In 2010 it purchasedFlorida-based DermaPet for US$64 million[4] andSussex-based Genitrix for £5 million.[5]
It sold its veterinary services business to US-firm,Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[6]
In June 2023, the private equity organisation,EQT AB, made an agreed takeover offer for the company which valued the company at £4.5 billion.[7] In December 2023, it was confirmed that all the necessary antitrust and regulatory approvals had been obtained and that the transaction would complete on 16 January 2024.[8]
The company sells various pharmaceuticals for common pets and farm animals – mainly for dogs, cats, equine and food producing animals. Their notable products includeVetoryl, a medicine forCushing's disease in dogs, andFelimazole, medicine forhyperthyroidism in cats. The company is organised into two regional divisions: European Pharmaceuticals and U.S. Pharmaceuticals.[9]
